Sab Biotherapeutics Inc (SABS) - News Archive

In a groundbreaking development in the field of immunotherapy for type 1 diabetes (T1D), SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced the establishment of a Clinica...

FDA Greenlights Groundbreaking IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics In a promising stride towards innovative treatments for Type 1 diabetes (T1D), SAB Biotherapeutics announced that...

SAB BioTherapeutics, a leading player in the development of advanced immunotherapies, recently provided a clinical trial update on SAB-142, an innovative type 1 diabetes T-cell immunotherapy.The groundbreaking biopharma...

SAB Biotherapeutics, Inc. (Nasdaq:SABS), a clinical-stage biopharmaceutical company known for its groundbreaking immunotherapy platform, recently unveiled a clinical partnership with the Navy Medical Research Command (N...

SAB Biotherapeutics Announces Reverse Stock Split to Boost Investor ConfidenceSIOUX FALLS, S.D., Jan. 02, 2024 - SAB Biotherapeutics, a clinical-stage biopharmaceutical company specializing in the development of a fully...

With the increasing prevalence of Type 1 diabetes worldwide, researchers and pharmaceutical companies are constantly striving to develop effective disease-modifying treatments. In a significant development, SAB Biothera...